Next-Generation Histone Deacetylase Inhibitors Header


Histone deacetylases (HDACs) have proven to be a promising target for drug intervention and there are a number of HDAC inhibitors (HDACi) currently being tested at various pre-clinical and clinical stages. HDACi were primarily developed as anti-tumor agents for cancer, but many are now being explored for treating neurodegenerative, immunologic, metabolic, inflammatory and cardiovascular disorders. More recently, they are being developed as combination treatments along with small molecule cancer immunotherapy agents. However, much remains to be elucidated about the functional implications of modulating HDACs and understanding the signaling pathways that are triggered downstream. Cambridge Healthtech Institute’s annual symposium on Next Generation Histone Deacetylase Inhibitors, tracks both the scientific and clinical progress being made to better understand the cellular function of this complex drug target family. The interactive sessions and panel discussions are all geared to provide ample opportunity for active networking, brainstorming and collaborating.

Preliminary Agenda


HDACi IN CANCER IMMUNOTHERAPY & COMBINATIONS

KEYNOTE PRESENTATION: Targeting HDACs and HATs for Cancer Therapy

Edward Seto, Ph.D., Professor, Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, George Washington University

HDACi Activate Innate Immune Cells and Regulatory Molecules

Ricky Johnstone Ph.D., Assistant Director of Research Division; Co-Head, Cancer Therapeutics Program and Head ¬ Gene Regulation Laboratory, Peter MacCallum Cancer Centre, Australia

Genetic and Pharmacologic Evidence of the Importance of HDAC8 Targeting in Tumor Immunotherapy

Wayne W. Hancock, M.D., Ph.D., Professor of Pathology and Chief of Transplant Immunology, Children's Hospital of Philadelphia and University of Pennsylvania

Enhancing the Anti-Cancer Activity of Oncolytic Viruses by Using Histone Deacetylase Inhibitors

Antonio Marchini, Ph.D., Principal Investigator, German Cancer Research Center (DKFZ)

Design and Development of Novel, Orally-Active, Selective HDAC6 Inhibitors for the Treatment of Cancer

Stephen Shuttleworth, Ph.D., CSO, Karus Therapeutics Ltd.

Entinostat Development: Targeting Immune Suppressor Cells to Expand Utility of Immune Checkpoint Inhibitors

Peter Ordentlich, Ph.D., CTO and Founder, Syndax Pharmaceuticals

Epigenetic Modulation of Immunotherapy: Advances in Clinical Translation

Pamela Munster, M.D., Professor, Department of Medicine; Director, Early Phase Clinical Trials Unit, and Leader, Developmental Therapeutics Program, University of California San Francisco


EMERGING HDAC CHEMISTRY & BIOLOGY

Light-controlled Modulation of Gene Expression by Chemical Optoepigenetic Probes

Ralph Mazitschek, Ph.D., Assistant Professor, Harvard Medical School and Co-Director of the Chemical Biology Platform, Center for Systems Biology, Massachusetts General Hospital

HDAC Inhibitors for Cardiometabolic Disease

Timothy A. McKinsey, Ph.D., Associate Professor and Associate Division Head for Translational Research, Department of Medicine, Division of Cardiology, University of Colorado Denver

HDAC Inhibitors in Neurodegeneration: Challenges and Progress

Berkley A. Lynch, Ph.D., Senior Director, CNS Research, Rodin Therapeutics

Talk Title to be Announced

Edward Holson, Ph.D., CSO, KDAc Therapeutics

Epigenetics in the Brain: Happier and Smarter Mice Through Inhibition of HDACs

Matthew Jarpe, Ph.D., Associate Vice President of Biology, Acetylon Pharmaceuticals




For more details on the conference, please contact:
Tanuja Koppal, Ph.D.
Conference Director
Cambridge Healthtech Institute
E: tkoppal@healthtech.com

For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Jon Stroup
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com